NDC-11 (Package) (Ascending) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00002-2980-26 | 00002-2980 | Selpercatinib | RETEVMO | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | May 8, 2020 | In Use | |
00002-2980-60 | 00002-2980 | Selpercatinib | RETEVMO | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | May 8, 2020 | In Use | |
00002-3977-60 | 00002-3977 | Selpercatinib | RETEVMO | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | May 8, 2020 | In Use | |
00002-4165-02 | 00002-4165 | Raloxifene Hydrochloride | Evista | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan. 6, 1998 | Dec. 31, 2017 | No Longer Used | |
00002-4165-07 | 00002-4165 | Raloxifene Hydrochloride | Evista | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan. 6, 1998 | Nov. 30, 2017 | No Longer Used | |
00002-4165-30 | 00002-4165 | Raloxifene Hydrochloride | Evista | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan. 6, 1998 | Jan. 31, 2018 | No Longer Used | |
00002-4165-34 | 00002-4165 | Raloxifene Hydrochloride | Evista | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan. 6, 1998 | Jan. 25, 2011 | No Longer Used | |
00002-4165-61 | 00002-4165 | Raloxifene Hydrochloride | Evista | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | June 10, 2010 | April 3, 2015 | No Longer Used | |
00002-4165-79 | 00002-4165 | Raloxifene Hydrochloride | Evista | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan. 6, 1998 | Jan. 25, 2011 | No Longer Used | |
00002-4165-99 | 00002-4165 | Raloxifene Hydrochloride | Evista | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Aug. 6, 2009 | March 5, 2012 | No Longer Used | |
00002-4184-02 | 00002-4184 | Raloxifene Hydrochloride | Evista | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Dec. 16, 2016 | Jan. 1, 2023 | In Use | |
00002-4184-07 | 00002-4184 | Raloxifene Hydrochloride | Evista | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Dec. 16, 2016 | Nov. 30, 2019 | In Use | |
00002-4184-30 | 00002-4184 | Raloxifene Hydrochloride | Evista | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Dec. 16, 2016 | In Use | ||
00002-4483-54 | 00002-4483 | Abemaciclib | Verzenio | 50.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | Oct. 6, 2017 | In Use | |
00002-4815-54 | 00002-4815 | Abemaciclib | Verzenio | 100.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | Oct. 6, 2017 | In Use | |
00002-5337-54 | 00002-5337 | Abemaciclib | Verzenio | 150.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | Oct. 6, 2017 | In Use | |
00002-5337-63 | 00002-5337 | Abemaciclib | Verzenio | 150.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | March 5, 2020 | In Use | |
00002-5340-60 | 00002-5340 | Selpercatinib | RETEVMO | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, RET | Oral | April 10, 2024 | In Use | |
00002-5562-60 | 00002-5562 | Selpercatinib | RETEVMO | 160.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, RET | Oral | April 10, 2024 | In Use | |
00002-6082-60 | 00002-6082 | Selpercatinib | RETEVMO | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, RET | Oral | April 10, 2024 | In Use | |
00002-6120-60 | 00002-6120 | Selpercatinib | RETEVMO | 120.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, RET | Oral | April 10, 2024 | In Use | |
00002-6216-54 | 00002-6216 | Abemaciclib | Verzenio | 200.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | Oct. 6, 2017 | In Use | |
00002-6902-30 | 00002-6902 | Pirtobrutinib | JAYPIRCA | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Oral | Jan. 27, 2023 | In Use | |
00002-7026-60 | 00002-7026 | Pirtobrutinib | JAYPIRCA | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Oral | Jan. 27, 2023 | In Use | |
00002-7026-99 | 00002-7026 | Pirtobrutinib | JAYPIRCA | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Oral | Feb. 15, 2023 | In Use |
Found 10,000 results in 2 milliseconds — Export these results